Bispecific Anti ErbB2/Anti cMet Antibodies
First Claim
1. A bispecific antibody that specifically binds to human ErbB-2 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-2 and a second antigen-binding site that specifically binds to human c-Met, wherein the bispecific antibody causes an increase in internalization of c-Met on OVCAR-8 cells of no more than 15% when measured after 1 hour of OVCAR-8 cell-antibody incubation as measured by a flow cytometry assay, as compared to internalization of c-Met on OVCAR-8 cells in the absence of antibody.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
28 Citations
13 Claims
- 1. A bispecific antibody that specifically binds to human ErbB-2 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-2 and a second antigen-binding site that specifically binds to human c-Met, wherein the bispecific antibody causes an increase in internalization of c-Met on OVCAR-8 cells of no more than 15% when measured after 1 hour of OVCAR-8 cell-antibody incubation as measured by a flow cytometry assay, as compared to internalization of c-Met on OVCAR-8 cells in the absence of antibody.
-
4. A bispecific antibody that specifically binds to human ErbB-2 and human C-met comprising a first antigen-binding site that specifically binds to human ErbB-2 and a second antigen-binding site that specifically binds to human c-Met, wherein
the first antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO: - 15, a CDR2H region with the amino acid sequence of SEQ ID NO;
16, and a CDR1H region with the amino acid sequence of SEQ ID NO;
17, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO;
18, a CDR2L region with the amino acid sequence of SEQ ID NO;
19, and a CDR1L region with the amino acid sequence of SEQ ID NO;
20; andthe second antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO;
21, a CDR2H region with the amino acid sequence of, SEQ ID NO;
22, and a CDR1H region with the amino acid sequence of SEQ ID NO;
23, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO;
24, a CDR2L region with the amino acid sequence of SEQ ID NO;
25, and a CDR1L region with the amino acid sequence of SEQ ID NO;
26. - View Dependent Claims (5, 7, 9, 11, 13)
- 15, a CDR2H region with the amino acid sequence of SEQ ID NO;
Specification